Login Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

  • Watchlist

    Keep track of companies that you follow and research.

  • 10 Years of Data

    Full access to our data with predictions and indicators that we calculate daily.

  • Screener

    Full access to our screener with tons of custom values and customizable email notifications.

  • XLS Exports

    Excel export of financials and screeners you define and save.

Subscribe now
Screener Weekly Summary

Cue Biopharma, Inc. CUE

Healthcare  —  Biotechnology
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Cue Biopharma, Inc. (CUE) Business Profile

Company Overview

Cue Biopharma, Inc. (CUE) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for treating cancer and autoimmune diseases. Founded in 2014, the company is headquartered in Cambridge, Massachusetts, a hub for biotechnology and pharmaceutical innovation. Cue Biopharma was established with the vision of leveraging the body’s immune system to selectively target and treat diseases while minimizing off-target effects. The company’s leadership team comprises seasoned professionals with extensive experience in immunology, drug development, and biotechnology. Key figures include Daniel Passeri, the Chief Executive Officer, and Anish Suri, the President and Chief Scientific Officer, both of whom bring a wealth of expertise in advancing immunotherapy solutions.

Core Business Segments

Cue Biopharma focuses on developing biologics that modulate the immune system to treat cancer and autoimmune diseases. The company’s proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform forms the backbone of its product pipeline. This platform is designed to selectively engage and modulate disease-relevant T cells, offering a novel approach to immunotherapy.

Oncology

In the oncology segment, Cue Biopharma is developing therapies that activate tumor-specific T cells to combat cancer. The lead candidate in this category is CUE-101, which targets HPV16-driven cancers, including head and neck squamous cell carcinoma. CUE-101 is currently in clinical trials and has shown promising results in selectively activating T cells to attack cancer cells while sparing healthy tissues.

Autoimmune Diseases

For autoimmune diseases, Cue Biopharma is working on therapies that aim to restore immune tolerance by selectively modulating autoreactive T cells. The company’s pipeline includes preclinical candidates designed to address diseases such as Type 1 diabetes and rheumatoid arthritis. These therapies leverage the Immuno-STAT™ platform to suppress harmful immune responses without compromising the overall immune system.

Immuno-STAT™ Platform

The Immuno-STAT™ platform is a versatile technology that underpins Cue Biopharma’s product development efforts. By engineering biologics that can selectively engage specific T cell populations, the platform enables the development of targeted therapies with reduced side effects. This technology has broad applications across oncology, autoimmune diseases, and infectious diseases.

Business Model

Cue Biopharma operates on a research-driven business model focused on the discovery, development, and commercialization of immunotherapies. The company generates revenue through strategic collaborations, licensing agreements, and potential future product sales. By partnering with leading pharmaceutical companies, Cue Biopharma leverages external expertise and resources to accelerate the development and commercialization of its therapies. Additionally, the company invests heavily in research and development to expand its pipeline and enhance the capabilities of its Immuno-STAT™ platform.

Strategic Direction

Cue Biopharma is committed to advancing its pipeline of immunotherapies and expanding the applications of its Immuno-STAT™ platform. The company’s strategic priorities include:

  • Clinical Development: Progressing its lead candidate, CUE-101, through clinical trials and advancing other pipeline candidates into clinical stages.
  • Partnerships and Collaborations: Establishing strategic alliances with pharmaceutical companies to co-develop and commercialize therapies.
  • Platform Expansion: Enhancing the Immuno-STAT™ platform to address a broader range of diseases, including infectious diseases.
  • Sustainability Goals: Incorporating sustainable practices in its operations and supply chain to minimize environmental impact.

Competitive Landscape

Cue Biopharma operates in a highly competitive biopharmaceutical sector, facing competition from both established companies and emerging startups. Key competitors include:

  • Bristol-Myers Squibb: A leader in immuno-oncology with a robust portfolio of checkpoint inhibitors.
  • Merck & Co.: Known for its blockbuster immunotherapy drug, Keytruda.
  • Adaptimmune Therapeutics: Focused on T cell receptor therapies for cancer.
  • Juno Therapeutics (a Bristol-Myers Squibb company): Specializes in CAR-T cell therapies.

Cue Biopharma differentiates itself through its proprietary Immuno-STAT™ platform, which offers a unique approach to selectively modulating T cells.

Risk Factors

Cue Biopharma faces several risks that could impact its operations and financial performance:

  • Clinical Trial Risks: The success of the company’s therapies depends on the outcomes of clinical trials, which are inherently uncertain.
  • Regulatory Challenges: Obtaining regulatory approval for new therapies is a complex and time-consuming process.
  • Market Dependence: The company’s financial performance is heavily reliant on the success of its lead candidates.
  • Supply Chain Disruptions: Delays or disruptions in the supply chain could impact the production of clinical trial materials.
  • Competition: Intense competition in the biopharmaceutical sector could limit market opportunities.

Recent Developments

Cue Biopharma has made significant progress in advancing its pipeline and expanding its strategic partnerships. Recent developments include:

  • Clinical Trials: The company has reported positive interim results from the Phase 1 clinical trial of CUE-101, demonstrating its potential efficacy and safety in treating HPV16-driven cancers.
  • Collaborations: Cue Biopharma has entered into research collaborations with leading academic institutions to explore new applications of the Immuno-STAT™ platform.
  • Corporate Strategy: The company has strengthened its leadership team and secured additional funding to support its R&D efforts.

Investment Considerations

Strengths

  • Innovative Platform: The Immuno-STAT™ platform offers a unique approach to immunotherapy, providing a competitive edge.
  • Strong Pipeline: A robust pipeline of candidates targeting high-value indications such as cancer and autoimmune diseases.
  • Experienced Leadership: A seasoned management team with a proven track record in drug development.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies enhance development and commercialization capabilities.

Risks

  • Early-Stage Company: As a clinical-stage company, Cue Biopharma has yet to generate significant revenue from product sales.
  • Regulatory and Clinical Risks: The success of the company’s therapies depends on regulatory approvals and clinical trial outcomes.
  • Market Competition: Intense competition from established players and emerging startups.

Conclusion

Cue Biopharma is at the forefront of developing innovative immunotherapies that leverage the body’s immune system to treat cancer and autoimmune diseases. With its proprietary Immuno-STAT™ platform, a strong pipeline, and strategic partnerships, the company is well-positioned to make a significant impact in the biopharmaceutical sector. While risks remain, Cue Biopharma’s innovative approach and commitment to advancing immunotherapy solutions provide a promising outlook for future growth.